文献速递肝病

代谢功能障碍相关脂肪性肝病与美国成人全因死亡率升高相关

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
PubMed 文献 · J Hepatol · 2021-08-08

该研究基于美国第三次国家健康与营养调查(NHANES III)7761名参与者随访至2015年的数据,比较MAFLD与NAFLD定义对全因及病因特异性死亡率的影响。中位随访23年,MAFLD与全因死亡率升高17%相关(HR 1.17,95%CI 1.04-1.32),而NAFLD本身未增加全因死亡风险。

要点

  • MAFLD患者全因死亡风险升高17%(HR 1.17,95%CI 1.04-1.32)。
  • 仅符合MAFLD定义者全因死亡风险升高1.66倍(HR 1.66,95%CI 1.19-2.32)。
  • NAFLD本身未增加全因死亡风险,MAFLD与心血管死亡风险升高相关。

核心结论

  • 在美国人群中,MAFLD与全因死亡率升高相关,而NAFLD在调整代谢危险因素后与全因死亡率无关联。

研究设计与样本

  • 基于美国第三次国家健康与营养调查(NHANES III)7761名参与者的队列研究,随访至2015年,中位随访23年,采用Cox比例风险模型分析。

主要发现

  • MAFLD患者全因死亡风险升高17%(HR 1.17,95%CI 1.04-1.32)。
  • MAFLD与心血管死亡风险升高相关。
  • NAFLD本身未增加全因死亡风险。
  • 同时符合两种定义者全因死亡风险升高(HR 1.13,95%CI 1.00-1.26)。
  • 仅符合MAFLD定义者全因死亡风险升高1.66倍(HR 1.66,95%CI 1.19-2.32)。

临床怎么用

  • 在代谢危险因素人群中,采用MAFLD定义可能有助于识别全因死亡风险升高的患者。
  • 对符合MAFLD定义但不符合NAFLD定义者,应关注其全因死亡风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recently, international experts proposed redefining non-alcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated fatty liver disease (MAFLD), based on modified criteria. It is suspected that outcomes such as mortality may differ for these clinical entities. We studied the impact of MAFLD and NAFLD on all-cause and cause-specific mortality in US adults. METHODS: We analyzed data from 7,761 participants in the Third National Health and Nutrition Examination Survey and their linked mortality through 2015. NAFLD was diagnosed by ultrasonographic evidence of hepatic steatosis without other known liver diseases. MAFLD was defined based on the criteria proposed by an international expert panel. The Cox proportional hazard model was used to study all-cause mortality and cause-specific mortality between MAFLD and NAFLD, with adjustments for known risk factors. RESULTS: During a median follow-up of 23 years, individuals with MAFLD had a 17% higher risk of all-cause mortality (hazard ratio [HR] 1.17; 95% CI 1.04-1.32). Furthermore, MAFLD was associated with a higher risk of cardiovascular mortality. NAFLD per se did not increase the risk of all-cause mortality. Individuals who met both definitions had a higher risk of all-cause mortality (HR 1.13, 95% CI 1.00-1.26), while individuals who met the definition for MAFLD but not NAFLD had a 1.7-fold higher risk of all-cause mortality (HR 1.66, 95% CI 1.19-2.32). Estimates for all-cause mortality were higher for those with advanced fibrosis and MAFLD than for those with advanced fibrosis and NAFLD. CONCLUSIONS: In this US population-based study, MAFLD was associated with an increased risk of all-cause mortality, while NAFLD demonstrated no association with all-cause mortality after adjusting for metabolic risk factors. LAY SUMMARY: Our findings provide further support for the idea that non-alcoholic fatty liver disease (NAFLD) is a part of a broader multi-system disease that also includes obesity, diabetes, high blood pressure, and high cholesterol. Therefore, re-defining NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) may help improve our understanding of predictors that increase the risk of death.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021. PMID: 34380057. doi:10.1016/j.jhep.2021.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。